Unidad de Alzheimer y otros trastornos cognitivos, Hospital Clínic de Barcelona, Barcelona, Spain.
Neurologia. 2011 Apr;26(3):143-9. doi: 10.1016/j.nrl.2010.09.011. Epub 2010 Nov 11.
We describe the 5 year experience of a genetic counselling program for familial dementias (the PICOGEN program).
The neurologist selected the candidates for genetic testing in the screening visit based on family history and phenotype (Alzheimer disease-AD, frontotemporal lobar degeneration-FTLD, or prion disease). Asymptomatic subjects who decided to know their genetic status were evaluated within a structured protocol by the psychiatrist and psychologist prior to entering the program and followed up afterwards.
A total of 87 patients from 72 families were candidates for the genetic study, 20 of the 72 families had a family history of autosomal dominant early-onset dementia (ADEOD). A pathogenic mutation was found in 22 patients (8 PSEN1, 1 PSEN2, 1 APP, 4 MAPT, 8 PRNP), 5 of which had not been previously described. All positive cases, except for 1 PSEN1 (12.5%) and 4 PRNP (50%) showed ADEOD. In 3 ADEOD cases (15%) no pathogenic mutation was found. After individual genetic counselling, 24/54 asymptomatic subjects at risk decided to have the pre-symptomatic study, of whom 10 (42%) were carriers of the pathogenic mutation. In the follow up, no major psychiatric complication was observed.
In our series, family history of ADEOD was a sensitive criterion for the detection of pathogenic mutations in AD and FTLD but not in prion diseases. No genetic anomalies were detected in 15% of the ADEOD cases using conventional diagnostic procedures, and 43% of pre-symptomatic subjects at risk who received individual genetic counselling decided to have the study. The pre-symptomatic diagnosis proved to be safe under these conditions.
我们描述了一个针对家族性痴呆症(PICOGEN 计划)的遗传咨询项目的 5 年经验。
神经科医生根据家族史和表型(阿尔茨海默病-AD、额颞叶变性-FTLD 或朊病毒病)在筛查就诊时选择进行基因检测的候选者。决定了解自己遗传状况的无症状受试者在进入该项目之前,通过精神病学家和心理学家进行结构化的评估,并在随后进行随访。
共有 87 名来自 72 个家庭的患者成为基因研究的候选者,其中 72 个家庭中有 20 个有常染色体显性早发性痴呆(ADEOD)家族史。在 22 名患者中发现了致病性突变(8 名 PSEN1、1 名 PSEN2、1 名 APP、4 名 MAPT、8 名 PRNP),其中 5 名以前未被描述过。除了 1 名 PSEN1(12.5%)和 4 名 PRNP(50%)为 ADEOD 外,所有阳性病例均显示 ADEOD。在 3 个 ADEOD 病例(15%)中未发现致病性突变。在个体遗传咨询后,24/54 名有风险的无症状受试者决定进行无症状前研究,其中 10 名(42%)是致病性突变的携带者。在随访中,未观察到重大精神并发症。
在我们的系列研究中,ADEOD 的家族史是检测 AD 和 FTLD 中致病性突变的敏感标准,但不是检测朊病毒病的敏感标准。在使用常规诊断程序的情况下,15%的 ADEOD 病例未检测到遗传异常,43%接受个体遗传咨询的有风险的无症状前受试者决定进行研究。在这些条件下,无症状前诊断被证明是安全的。